Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biotechnology

Lilly, Anima link for translation control

by Lisa M. Jarvis
July 27, 2018 | A version of this story appeared in Volume 96, Issue 31

 

Eli Lilly & Co. and Anima Biotech have teamed to develop small-molecule translation inhibitors for undisclosed protein targets. In exchange for a $30 million up-front fee and $14 million in research funding, Anima will use its technology platform to look for small molecules that can block the translation—and thereby prevent the production—of certain proteins identified by Lilly.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.